Duke Cancer Trials Details

February 4th, 2011

We have had a lot of concerned patients contact us with questions about the Duke University clinical trials that are currently being investigated by us, as well as by the national Institute of Medicine.

The specific names and NCT numbers of the questioned trials are listed below. The numbers are important because they will be printed on any signed consent forms.

  1. NCT00636441 – Early Stage Breast Cancer. Brief Title: Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer.   Official title: A Randomized Phase II Trial Evaluating the Performance of Genomic Expression Profiles to Direct the Use of Preoperative Chemotherapy for Early Stage Breast Cancer.
  2. NCT00509366 – Stage IIIB/IV Non-Small Cell Lung Cancer. Brief title: Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer (TOP0602).  Official title: Phase II Prospective Study Evaluating the Role of Pemetrexed Plus Gemcitabine Chemotherapy for the Initial Treatment of Select Stage IIIB and IV NSCLC in Patients Using a Genomic Predictor of Platinum Resistance to Guide Therapy.
  3. NCT00545948 – Early Stage Non-Small Cell Lung Cancer. Brief title: Adjuvant Cisplatin With Either Genome-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small Cell Lung Cancer (TOP0703).  Official title: Genome-Guided Phase II Study of Cisplatin Based Adjuvant Chemotherapy With Either Vinorelbine or Pemetrexed for Early Stage Non-Small Cell Lung Cancer.

If you participated in these trials and have any questions about your legal rights, please don’t hesitate to contact HensonFuerst Attorneys at 1-800-4LAW-MED. We’re available 24/7. Or, visit our website at http://www.lawmed.com/.  If you have questions, HensonFuerst has answers.